Market Cap 13.63B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 16.56
Forward PE 14.23
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 715,700
Avg Vol 1,525,998
Day's Range N/A - N/A
Shares Out 661.97M
Stochastic %K 97%
Beta 1.07
Analysts Sell
Price Target $32.44

Latest News on GMAB

Transactions in Connection with Share Buy-back Program

Apr 22, 2025, 7:23 AM EDT - 5 days ago

Transactions in Connection with Share Buy-back Program


Genmab's Outlook Beyond Darzalex's Patent Cliff

Apr 15, 2025, 7:36 AM EDT - 12 days ago

Genmab's Outlook Beyond Darzalex's Patent Cliff


Genmab A/S Share Capital Reduction

Apr 10, 2025, 12:20 PM EDT - 17 days ago

Genmab A/S Share Capital Reduction


Transactions In Connection with Share Buy-back Program

Apr 7, 2025, 7:43 AM EDT - 20 days ago

Transactions In Connection with Share Buy-back Program


Transactions in connection with share buy-back program

Mar 31, 2025, 8:18 AM EDT - 27 days ago

Transactions in connection with share buy-back program


Genmab Announces Initiation of Share Buy-Back Program

Mar 25, 2025, 5:28 PM EDT - 4 weeks ago

Genmab Announces Initiation of Share Buy-Back Program


Passing of Genmab A/S' Annual General Meeting

Mar 12, 2025, 10:23 AM EDT - 6 weeks ago

Passing of Genmab A/S' Annual General Meeting


Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

Feb 14, 2025, 9:32 AM EST - 2 months ago

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript


Notice to Convene the Annual General Meeting of Genmab A/S

Feb 13, 2025, 6:00 AM EST - 2 months ago

Notice to Convene the Annual General Meeting of Genmab A/S


Genmab Publishes 2024 Annual Report

Feb 12, 2025, 11:01 AM EST - 2 months ago

Genmab Publishes 2024 Annual Report


Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Jan 22, 2025, 6:23 AM EST - 3 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024


Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Dec 11, 2024, 8:20 AM EST - 4 months ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting


Genmab Is Too Attractive To Ignore

Dec 8, 2024, 8:12 AM EST - 5 months ago

Genmab Is Too Attractive To Ignore


Genmab to Present at Citi's Global Healthcare Conference

Nov 25, 2024, 11:06 AM EST - 5 months ago

Genmab to Present at Citi's Global Healthcare Conference


Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

Nov 9, 2024, 4:38 PM EST - 6 months ago

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript


Genmab: Looking To Manage My Position Around Q3 Earnings

Nov 6, 2024, 3:17 AM EST - 6 months ago

Genmab: Looking To Manage My Position Around Q3 Earnings


Genmab to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 1:11 PM EST - 6 months ago

Genmab to Present at Jefferies London Healthcare Conference


Major Shareholder Announcement

Oct 4, 2024, 1:55 PM EDT - 7 months ago

Major Shareholder Announcement


Genmab A/S (GMAB) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 9:48 AM EDT - 9 months ago

Genmab A/S (GMAB) Q2 2024 Earnings Call Transcript


Genmab Announces Financial Results for the First Half of 2024

Aug 8, 2024, 11:03 AM EDT - 9 months ago

Genmab Announces Financial Results for the First Half of 2024


Genmab Updates 2024 Financial Guidance

Aug 8, 2024, 11:00 AM EDT - 9 months ago

Genmab Updates 2024 Financial Guidance